Setting Up Sports Nutrition Factory in Indonesia: Ownership, KBLI, and Licences

Begin with a sellable SKU register, not a factory label

“Sports nutrition factory” is a commercial description, not a single Indonesian regulatory category. A launch range can contain ready-to-drink products, powdered drink mixes, protein bars, gels, capsules and tablets. Their ingredients, presentation and claims may place them in processed food or health-supplement pathways, and the manufacturing processes may point to different industrial classifications. The first useful project document is therefore a controlled SKU register rather than a generic incorporation brief.

For each launch SKU, record the complete quantitative formula, ingredient function and source, daily use, physical form, serving instructions, target consumer, claims, pack size, shelf-life basis and every transformation performed at the Indonesian site. Identify imported premixes and whether the local plant merely packs them or carries out blending, thermal treatment, extrusion, compression, encapsulation or beverage filling. That distinction affects the KBLI analysis and the evidence expected from the facility.

One portfolio can contain several regulatory routes, even when every label uses the same sports brand. Grouping the range by marketing theme can hide a material dependency: a food line may be technically ready while a supplement line still lacks an eligible facility scope. Give each SKU a stable identifier and a route version, then require regulatory, engineering, procurement and marketing teams to refer to the same record.

Separate processed-food SKUs from supplement SKUs

Classification should start with the product dossier, not the desired approval speed. A conventional protein bar, flavoured sports drink or carbohydrate gel may follow the processed-food regime when its composition, presentation and claims fit that category. A tablet, capsule or concentrated powder presented to supplement nutritional needs may instead be assessed as a health supplement. Borderline powders are especially sensitive because the same physical form can be a food ingredient, a powdered beverage or a supplement depending on composition, dose, directions and claims.

BPOM Regulation 23/2023 is the current processed-food registration framework and replaced the earlier registration rules identified in the regulation. It should be read together with the relevant product category, production-facility evidence and the service shown in the live BPOM system. For health supplements, BPOM Regulation 32/2022 , as amended, addresses safety, benefit, quality and labelling requirements. The two routes are not interchangeable product-number formats; they evaluate different legal categories.

Build two evidence lanes from the start. The processed-food lane should connect food-category placement, CPPOB or the currently applicable facility evidence, ingredient legality, nutrition and claim rules, label particulars and the processed-food authorisation. The supplement lane should connect the accepted supplement formula and dosage form, the manufacturer’s relevant GMP or special food-facility approval, safety and benefit support, specifications, stability and the supplement authorisation. A contract manufacturer does not eliminate this split; it only changes who supplies some of the facility evidence.

Escalate boundary cases before artwork or equipment is fixed

Escalate when the product uses a novel or tightly controlled substance, combines concentrated actives with food ingredients, carries physiological or performance claims, or resembles a measured supplement regimen. Ask what category the complete product belongs to, not how to force it into the factory’s preferred code. Complete SKU-by-SKU classification before treating the licence stack as final.

• Preserve the formula and proposed label that were actually assessed; a later marketing change may reopen the category question.
• Do not use a food authorisation assumption for capsules or tablets merely because the ingredients are familiar foods.
• Do not present an ordinary processed food with an unapproved disease, recovery or performance promise to make it look like a supplement.
• Record the unresolved point, responsible reviewer, evidence requested and a decision deadline for every borderline SKU.

Map each production line to KBLI 2025 and ownership eligibility

Once the SKU routes are provisionally locked, map the actual activity performed at the plant to the current KBLI 2025 descriptions. The OSS KBLI 2020-to-2025 conversion guidance matters because familiar legacy codes may no longer describe the current activity. A copied consultant memo or an old NIB is not enough for a new project; check the current OSS page, conversion treatment, scope and risk-based obligations.

For example, KBLI 2025 11053 for soft-drink manufacturing includes flavoured or sweetened non-alcoholic drinks and powdered soft drinks. OSS records that former KBLI 11040 changed to 11053 in KBLI 2025. A ready-to-drink sports beverage or drink mix may be examined against that scope, while milk-based beverages, fruit juice and other excluded processes may point elsewhere. The word “drink” alone does not settle the code.

KBLI 2025 10799 expressly includes specified protein food products such as soy protein, textured vegetable protein and hydrolysed vegetable protein, as well as probiotics and other residual food activities. That makes it relevant to some upstream protein products, but it is not a universal code for every retail protein powder, bar or premix. Select the code that describes the site’s principal production process, including any more specific food, dairy, confectionery or beverage classification that actually applies. A supplement line within the pharmaceutical scope may instead require assessment under KBLI 2025 21012 .

Presidential Regulation 49/2021 uses a general openness framework subject to the investment schedules and sector conditions. Test every selected KBLI rather than declaring the entire “sports nutrition industry” open. This is critical if a natural-product route points to KBLI 21022: Annex III lists 21022 as a 100% domestic-capital activity. A foreign-owned project should redesign the lawful product and production model, or use an eligible independent manufacturer, instead of masking the restriction through nominee ownership.

When the route is established, align the deed, AHU record, tax details, OSS profile, NIB, KBLI, project location and line capacity. The general corporate layer is explained under registering a company in Indonesia , but incorporation does not replace sector or product approval. Add only activities the business can substantiate; an oversized KBLI list creates no authority to manufacture an unapproved category.

Configure the site for portfolio segregation and cross-contact control

A mixed sports-nutrition plant is a movement-control problem before it is a room-count problem. Plot people, raw materials, allergens, packaging, waste, samples, returned goods and released stock on the same plan. Whey, soy, egg, nuts, gluten-containing materials, caffeine, vitamins, botanical extracts and high-intensity sweeteners create different cross-contact and dosing risks. The plant must be able to demonstrate that zoning, scheduling, containment, cleaning and verification reduce those risks for the proposed product families.

Start with incoming-material status. Distinguish quarantine, sampled, approved, rejected and returned stock physically or through a validated control system. Weighing and dispensing need protection against mix-ups and dust migration; high-potency or low-dose additions require equipment and reconciliation appropriate to their risk. Map rework rules by product family rather than assuming that material can move between food and supplement batches. Warehouse status and label control should prevent a technically finished batch from being mistaken for a legally releasable one.

The risk-based business licensing system is now governed by Government Regulation 28/2025 . Enter the real activity, scale, location and project data in OSS, then complete the resulting spatial, environmental, building, industrial and supporting obligations. A landlord’s existing documents should be checked for address, holder, activity and capacity; they are not automatically transferable evidence for the tenant’s new lines.

Translate unresolved approval assumptions into lease conditions precedent. Examples include a usable spatial result, acceptable environmental pathway, sufficient utilities, lawful building use, ability to install wastewater or dust controls, and no estate rule that blocks the chosen process. The more varied the portfolio, the more valuable a staged fit-out becomes: qualify the first defensible line and leave future rooms outside the initial approved scope until their products and controls are ready.

Run parallel licence workstreams without confusing completion

The project schedule should show dependencies, not one undifferentiated “licensing” bar. The corporate and OSS workstream establishes the lawful operator and registered activities. The premises workstream addresses location, environmental, building and industrial requirements. The facility-quality workstream demonstrates the applicable production standard. The product workstream secures the authorisation for each SKU. Halal, standards, utilities and local operational requirements form additional tracks where applicable.

Sequence the evidence so that a later task does not invalidate an earlier one. Facility drawings should follow the classified portfolio and process map. Equipment acceptance should preserve the hygienic and containment assumptions used in the facility submission. Product dossiers should cite the actual manufacturer and authorised scope. Commercial artwork should be generated from the approved master, not the other way around. If a supplier, formula or pack changes during review, route it through change control and identify every dependent submission.

Halal planning deserves its own critical path because materials, processing aids, cleaning agents, shared equipment and suppliers all affect the evidence. BPJPH has stated that the final transition for specified categories, including micro and small food-and-beverage businesses and imported products, ends on 17 October 2026, without a further extension. The BPJPH implementation notice should not be misread as permission for every larger manufacturer to wait; determine the phase already applicable to the entity and each SKU, and design the assurance system before supplier approval.

Create a licence register with official service name, applicant, site, scope, portal identifier, payment and submission status, outstanding query, issue date, conditions, expiry and renewal owner. A receipt proves only that a file entered a system. Close each row with the final valid output and a scope comparison against the commercial plan.

Control claims, formulas, and artwork as one evidence set

Sports-nutrition value propositions often depend on claims, which means regulatory review cannot be left until packaging procurement. Build a claim register for the product name, front-of-pack descriptors, nutrition claims, functional statements, preparation directions, serving size, target consumer, warnings, endorsements and digital advertising. Link each statement to the classified product category, permitted wording, compositional condition, calculation or test method, substantiation file and final approval state.

For processed foods, BPOM Regulation 1/2022 governs claims on processed-food labels and advertisements. A product’s nutrient content does not automatically permit every performance expression that marketing can derive from it. For health supplements, the safety, benefit, quality and labelling framework follows the supplement route and the approved dossier. Keep the two claim libraries separate even if a master brand spans both categories.

The formula record should reconcile the laboratory or pilot formula, manufacturing bill of materials, ingredient specifications, overages, processing loss, declared nutrition, serving directions and stability protocol. For a flavoured range, decide whether each flavour changes allergens, active levels, sweeteners, colours or claims. For imported premixes, obtain composition and specification access early enough to support the Indonesian dossier; a certificate of analysis without formulation transparency may not resolve classification or label calculations.

Use one controlled artwork master per authorised SKU and compare printer proof, production file and released label against it. Reconcile label quantities batch by batch and destroy obsolete versions under record. The most dangerous mismatch is a technically compliant formula sold under unapproved directions or claims, because the plant may pass process checks while the product placed on the market no longer matches its authorisation.

Commission and release the portfolio line by line

Commissioning converts design assumptions into operating evidence. Start with utilities and measurement systems, then qualify equipment and challenge the process with the intended ranges of batch size, ingredient characteristics and packaging speed. A blender that produces uniform carbohydrate powder may need a different sampling and cleaning challenge for low-dose micronutrients. A beverage filler may require microbial controls irrelevant to a dry bar line. Validation should therefore follow the SKU-family risk map, not a single generic factory protocol.

Build a release packet for every SKU family

1. Confirm that the operator, address, KBLI and production line match the final OSS and premises records.
2. Verify that the facility certificate or approval covers the product category, dosage form, process and shared-use arrangement actually employed.
3. Complete equipment, utility, cleaning, method and process evidence required by the applicable quality system.
4. Approve suppliers and materials, including identity, specification, allergen, halal and traceability attributes relevant to the product.
5. Reconcile the commercial formula, master manufacturing record, test specification, stability commitment and final authorised label.
6. Run the batch review, deviation assessment and legal-release check independently of sales or launch pressure.

Use three statuses: technically qualified, regulatorily authorised and commercially released. They answer different questions. A successful engineering batch may be technically qualified but cannot be sold. A product authorisation may exist while the line change or label version is not ready. Commercial release should require both earlier statuses plus final batch conformity, traceability and the applicable distribution conditions.

Introduce hold points for common failure modes: facility scope names a different dosage form; the authorised manufacturer is not the actual plant; an active supplier differs from the dossier; stability does not support the planned shelf life; halal evidence does not cover the new source; or marketing has changed the claim after approval. Give quality the authority to stop the affected SKU without stopping unrelated lines that have complete packets.

This line-by-line method also improves launch sequencing. The business can prioritise a lower-complexity processed-food SKU while a supplement dossier continues, provided the site and licence conditions allow that separation. The broader food and beverage manufacturing registration framework provides context for the company, factory and product layers, while the present control remains portfolio-specific: no SKU inherits permission from a neighbouring product.

Decide whether one Indonesian factory can carry the portfolio

A single factory is viable when the launch SKUs can be classified with confidence, their production activities can be registered under ownership-eligible KBLIs, the site can segregate the resulting risks, and every product has a credible facility and authorisation path. Shared utilities and warehouses may create economies, but they do not erase separate standards or scope restrictions. The decision should compare the evidence burden and change risk, not merely the number of rooms.

Choose a phased model when the processed-food portfolio is stable but supplements or concentrated actives remain uncertain. Reserve expansion space, qualify only the initial line, and use formal change control before bringing a second category into the building. Choose contract manufacture where the central uncertainty is specialised dosage-form capability or early demand, but verify the partner’s exact approved scope, dossier access, supplier-change procedure, batch-release responsibility, complaints and recall interface.

Do not proceed with one plant merely because a broad business description appears in OSS. Stop if the selected code does not describe the real transformation, a PT PMA depends on a restricted activity, the facility cannot control cross-contact, the claim strategy would change the category, or the product approval cannot name the actual manufacturer and formula. The go decision is a complete release path for every launch SKU, not an NIB for the company.

The immediate management action is to approve the SKU control board and nominate an owner for each unresolved gate. Only then should the board release an unconditional lease, equipment purchase or launch commitment. If one SKU fails, retain it in redesign or outsource it while the other fully supported SKUs advance; that is the advantage of governing the portfolio one product at a time.